MedTrace Logo

Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma

NCT03834623 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-10-05

Study results available
· View outcomes & findings →

Summary

This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune response).

Conditions

Interventions

DRUG

CC-122

Oral CC-122 at 2 mg daily, 5 days out of 7

DRUG

Nivolumab

240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Celgene Corporation

    collaborator INDUSTRY

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Nikhil Khushalani, MD · H. Lee Moffitt Cancer Center and Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-14
Primary Completion
2021-06-29
Completion
2021-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03834623 on ClinicalTrials.gov